A recently published study found that supplementation with branded bacteriophage, PreforPro, enhanced the effects of probiotics.
Photo © iStockphoto.com/Raycat
A recently published study1 found that supplementation with bacteriophages (PreforPro from Deerland Enzymes & Probiotics, Kennesaw, GA) enhanced the effects of Bifidobacterium animalis subsp. lactis (B. lactis). In 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial, 68 participants were randomized to receive either placebo, 1 billion CFU of B. lactis BL04, or 1 billion CFU of B. lactic BL04 with 15 mg of PreforPro, once per day. Primary outcomes included self-assessments of GI health, a daily stool log, and 16s rRNA analysis of gut microbial populations.
Results showed that compared to placebo there was a significant main effect for time in perceived improvements in GI inflammation and a significant reduction in average symptom severity in the B. lactis + PreforPro group. While not significant, researchers also observed a trend toward improved colon pain in subjects taking the combined treatment. Additionally, there was a larger increase in Lactobacillus and short-chain fatty acid-producing microbial taxa detected in the stool of participants taking PreforPro with B. lactiscompared to the probiotic alone.
The study suggests that PreforPro alters the gut ecology, extending the GI benefits of probiotics. “This study demonstrates the opportunity and capability of phages in the robust support of healthy microflora balance and the associated physiological benefits,” said John Deaton, vice president of science and technology for Deerland Probiotics & Enzymes, in a press release. “Phages are clearly up-and-coming supplements in the rapidly burgeoning arena of microbiome support.”
Reference
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”